Peter Eickelmann

USPTO Granted Patents = 25 (Patent Applications = 20)

CIPO Patents = 4

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 4.8

ph-index = 19

Forward Citations = 1,123(Granted Patents)

Company Filing History:

23 out of 1,535

Boehringer Ingelheim International Gmbh

Solvay Pharmaceuticals, Gmbh

patents

where one patent can have more than one assignee

Years Active: 2008-2024

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12115179 - Pharmaceutical composition, methods for treating and uses thereof (2024-10-15),

2. 10406172 - Pharmaceutical composition, methods for treating and uses thereof (2019-09-10),

3. 8772323 - Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists (2014-07-08),

4. 8557782 - Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture (2013-10-15),

5. 8513264 - Combination therapy for the treatment of diabetes and related conditions (2013-08-20),

6. 8039441 - Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture (2011-10-18),

7. 7879807 - Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture (2011-02-01),

8. 7879806 - Glucopyranosyl-substituted benzyl-benzonitrile derivates, medicaments containing such compounds, their use and process for their manufacture (2011-02-01),

9. 7858587 - Glucopyranosyl-substituted difluorobenzyl-benzene derivates, medicaments containing such compounds, their use and process for their manufacture (2010-12-28),

10. 7851602 - Glucopyranosyl-substituted ((hetero)cycloalkylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture (2010-12-14),

11. 7838500 - Crystalline form of 1'-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments (2010-11-23),

12. 7776830 - Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture (2010-08-17),

13. 7772378 - Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture (2010-08-10),

14. 7767692 - 1-amidomethylcarbonyl-piperidine compounds, methods and intermediate products for the production thereof and pharmaceutical formulations containing said compounds (2010-08-03),

15. 7745414 - Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture (2010-06-29),

Title: Peter Eickelmann: Pioneering Innovations in Pharmaceuticals and Biotechnology

Introduction:

Peter Eickelmann, a visionary inventor based in Mittelbiberach, DE, is renowned for his dedication to pushing the boundaries of what is possible through his remarkable inventions and innovations. With an impressive portfolio of 24 patents, Eickelmann's pioneering work continues to inspire future generations of inventors and researchers globally.

Latest Patents:

Among his latest patents is a groundbreaking pharmaceutical composition designed to treat a myriad of metabolic disorders and related conditions. This composition includes an SGLT2 inhibitor, a DPPIV inhibitor, and a third antidiabetic agent, offering new possibilities in the treatment and prevention of diabetes mellitus and hyperglycemia. Additionally, Eickelmann has developed benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists, demonstrating his innovative approach to addressing critical medical needs.

Career Highlights:

Throughout his illustrious career, Peter Eickelmann has made significant contributions to the fields of pharmaceuticals and biotechnology. He has been instrumental in advancing research and development at prestigious companies such as Boehringer Ingelheim International GmbH and Ajinomoto Co., Ltd. Eickelmann's expertise and visionary mindset have led to groundbreaking discoveries that have the potential to revolutionize the healthcare industry.

Collaborations:

In his pursuit of innovation, Peter Eickelmann has had the privilege of collaborating with esteemed professionals in the field. Notable coworkers such as Leo Thomas and Frank Himmelsbach have brought diverse perspectives and expertise to Eickelmann's projects, contributing to the success of his pioneering inventions.

Conclusion:

Peter Eickelmann's relentless pursuit of innovation and unwavering commitment to advancing the frontiers of science underscore his status as a trailblazing inventor in the pharmaceutical and biotechnology sectors. His groundbreaking patents and collaborative efforts continue to inspire and shape the future of medical research, leaving an indelible mark on the global innovation landscape.

This text is generated by artificial intelligence and may not be accurate.